Abstract:There has been growing clinical evidence of the value of targeted alpha therapy for treatment of several cancers. The work has been slowed by the lack of availability of the key alpha emitting isotopes, especially Ac-225. Until this time, most of the supply has been from three Th-229 generators that are milked to produce hundreds of mCi of Ac-225 every month. There has been a growing effort to produce new sources of Ac-225 from several different accelerator-based routes. It can be produced with medical-isotope cyclotrons with a proton energy of at least 16 MeV using the reaction Ra-226(p,2n)Ac-225. It can also be produced by using high-energy protons (150 to 800 MeV) for spallation of a thorium target. Significant experimental work has been applied to both processes. It can also be produced by the photonuclear reaction, Ra-226({\gamma},n)Ra-225. The Ra-225 decays via beta decay to Ac-225 with a half life of 14.9 days. The photons are produced by an intense beam of electrons with an energy about 25 to 30 MeV. This paper will provide a technical description of radium targets and a target chamber that would be capable of producing a yield of four curies of Ra-225 from a 10-day irradiation of one gram of radium segmented into two to four separate encapsulated targets, at a beam power of 20 kW. These targets could be milked at least three times, yielding nearly four curies of Ac-225. There is also a description of a method to reduce production of Ac-227 to values less than a few parts per million of the yield of Ac-225. The Monte Carlo code Fluka has been used to model the yields of Ra-225 and support the design concept to reduce the production of Ac-227. It has also been used to model the experimental results by Maslov et al. [<a class="link-external link-https" href="https://doi.org/10.1134/S1066362206020184" rel="external noopener nofollow">this https URL</a>] to provide reasonable confidence in the cross-section value used by the code.

A new method in the production of Ac-227, Ra-228, Th-228 and U-232 on Thorium target from different perspective for use in Radioisotope Power Systems and Nuclear Batteries

Study on Production Method of the {sup 178m2}hf Isomer for Induced Gamma Emission

Semi-Permanent Mass Production of Ac-225 for Cancer Therapy by the (3n,x) Reaction in Pressurized Water Reactor

Production of Polonium-208, 209 and 210 for use in nuclear battery via particle accelerator

Production of nuclear sources and nuclear batteries by proton irradiation

Production of Pa-U Fuel with Proliferation Resistance by 14 MeV Neutron for Long-life Core

Actinium-225 Production with an Electron Accelerator

Effect of 226Ra purity as a target for 225Ac production using a fast reactor

Possibility assessment for production of non-traditional nuclear fuel in thorium blanket of hybrid thermonuclear reactor

Potential production of Ac-225 at Egyptian second research reactor (ETRR-2) through neutron induced transmutation of Ra-226

Production of 230U/226Th for targeted alpha therapy via proton irradiation of 231Pa

226Ra irradiation to produce 225Ac and 213Bi in an accelerator-driven system reactor

225Ac production via 226Ra (μ−, n ν) 225Fr reaction with 226Ra target

Actinium-225 photonuclear production in nuclear reactors using a mixed radium-226 and gadolinium-157 target

Defining Processing Times for Accelerator Produced 225Ac and Other Isotopes from Proton Irradiated Thorium

Research and Development for Cyclotron Production of 225Ac from 226Ra—The Challenges in a Country Lacking Natural Resources for Medical Applications

Dependence of neutron rate production with accelerator beam profile and energy range in an ADS-TRIGA RC1 reactor

Physical aspects for involvement of thermonuclear reactors into nuclear power systems

Cross sections of proton-induced neutron emission reactions on thorium and uranium at energies below 18 MeV

Investigation of production of medical 82Sr and 68Ge for 82Sr/82Rb and 68Ge/68Ga generators via proton accelerator

Nuclear data for light charged particle induced production of emerging medical radionuclides